A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)

Relapse remains the major cause of death in older patients transplanted for Acute Myeloid Leukemia (AML) in first complete remission (CR1) or for patients with advanced Myelodysplastic Syndrome (MDS) at any age. Conventional myeloablative conditioning followed by allogeneic blood or marrow transplan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Vij, Ravi, Le-Rademacher, Jennifer, Laumann, Kristina, Hars, Vera, Owzar, Kouros, Shore, Tsiporah, Vasu, Sumithira, Cashen, Amanda, Isola, Luis, Shea, Thomas, DeMagalhaes-Silverman, Margarida, Hurd, David, Meehan, Kenneth, Beardell, Frank, Devine, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790289/
https://ncbi.nlm.nih.gov/pubmed/31212080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados